Interpreting rheumatoid factor and anti-CCP antibodies
What RF and anti-CCP detect, their sensitivity and specificity, the low- versus high-positive cut-off (3 times the upper limit) in the 2010 ACR/EULAR criteria, the many non-RA causes of a positive RF, prognostic meaning of double positivity, and anti-CCP-positive arthralgia without arthritis.
Tier 2Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Anti-CCP is the specific test (about 95 to 98%). RF is less specific (about 85%) because many chronic inflammatory and infective states produce it.
- Both have sensitivity of about 60 to 80% in established RA and less in early disease. Around 20 to 30% of RA is seronegative, so a negative result never excludes it in a patient with synovitis.
- Serology carries up to 3 of the 10 points in the 2010 ACR/EULAR criteria, and predicts erosions and extra-articular disease.
Loading the rest of the note…
Finished reading?
Sources
- Nishimura K et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808Annals of Internal Medicine, 2007
- Therapeutic Guidelines: Rheumatology (rheumatoid arthritis)AU/NZTherapeutic Guidelines Limited, current online version, accessed November 2026
- RCPA Manual: rheumatoid factor and cyclic citrullinated peptide antibodiesAU/NZRoyal College of Pathologists of Australasia, online, accessed November 2026
- Australian Rheumatology Association information and position statementsAU/NZAustralian Rheumatology Association, online, accessed November 2026
- Aletaha D et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8ACR and EULAR, 2010 (current; no replacement published by November 2026)
- Smolen JS et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2025 update. Ann Rheum Dis 2026;85:991-1009EULAR, 2025 (published 2026)
- Cope AP et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 2024;403:838-49The Lancet, 2024
- Steiner G et al. Should ACR/EULAR criteria be revised changing the RF and ACPA scores? Autoimmun Rev 2024;23:103421Autoimmunity Reviews, 2024
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback